Stay well informed

Investor News

We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.0.105″ background_layout=“light“] HAEMATO AG is a listed pharmaceutical company with focus on the growth markets of high-end specialty pharmaceuticals in the indication groups of oncology and HIV as well as in the areas of rheumatism, neurology and …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.0.105″ background_layout=“light“] HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of patent-free and patent-protected drugs primarily in the high-price indicative areas of oncology and HIV as well as in the areas of …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.0.105″ background_layout=“light“] In today’s meeting, the Supervisory Board of HAEMATO AG („HAEMATO“ or the „Company“) accepted the wish of Dr. Christian Pahl to not extend his contract as Management Board Member beyond the current term ending 31 July …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.7″] IFRS result Q1 2017, sales EUR 67.9 million (previous year: EUR 67.9 million), EBIT EUR 2.8 million (previous year: EUR 3.5 million) HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 67.9 million in the first quarter …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.7″] HAEMATO AG: Capital increase from authorized capital under exclusion of existing shareholders‘ subscription rights resolved and successfully implemented. The Management Board of HAEMATO AG, Schönefeld, (ISIN: DE0006190705) decided today with the …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.7″] How can you live a carefree life with 150,000 euros? Quite simply – bet on the right shares with a decent dividend yield. The experts at FOCUS-MONEY show how easy this is. Read the article [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us